Coya Therapeutics (NASDAQ:COYA) Posts Earnings Results, Beats Estimates By $0.14 EPS

Coya Therapeutics (NASDAQ:COYA) posted its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14, Zacks reports.

Coya Therapeutics Price Performance

NASDAQ COYA traded down $0.11 during trading hours on Tuesday, reaching $6.74. The company’s stock had a trading volume of 3,384 shares, compared to its average volume of 96,359. The firm has a fifty day simple moving average of $6.29 and a 200-day simple moving average of $6.48. The stock has a market cap of $112.54 million, a P/E ratio of -10.36 and a beta of 0.31. Coya Therapeutics has a 52 week low of $4.75 and a 52 week high of $10.42.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. Chardan Capital reissued a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a report on Thursday, February 6th. D. Boral Capital reissued a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Tuesday.

About Coya Therapeutics

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.